Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

Similar articles for PubMed (Select 23375568)

1.

Focal hemosiderin deposits and β-amyloid load in the ADNI cohort.

Kantarci K, Gunter JL, Tosakulwong N, Weigand SD, Senjem MS, Petersen RC, Aisen PS, Jagust WJ, Weiner MW, Jack CR Jr; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2013 Oct;9(5 Suppl):S116-23. doi: 10.1016/j.jalz.2012.10.011. Epub 2013 Jan 30.

2.

Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.

Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ, Shaw LM, Trojanowski JQ, Zetterberg H, Blennow K, Weiner MW; Alzheimer's Disease Neuroimaging Initiative*.

Brain. 2015 Mar;138(Pt 3):772-83. doi: 10.1093/brain/awu367. Epub 2014 Dec 24.

PMID:
25541191
3.

Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.

Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman EM, Davis MD, Grundman M, Sabbagh MN, Sadowsky CH, Fleisher AS, Carpenter A, Clark CM, Joshi AD, Mintun MA, Skovronsky DM, Pontecorvo MJ; AV45-A11 Study Group.

Neurology. 2012 Oct 16;79(16):1636-44. doi: 10.1212/WNL.0b013e3182661f74. Epub 2012 Jul 11.

4.

Improved power for characterizing longitudinal amyloid-β PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region.

Chen K, Roontiva A, Thiyyagura P, Lee W, Liu X, Ayutyanont N, Protas H, Luo JL, Bauer R, Reschke C, Bandy D, Koeppe RA, Fleisher AS, Caselli RJ, Landau S, Jagust WJ, Weiner MW, Reiman EM; Alzheimer’s Disease Neuroimaging Initiative.

J Nucl Med. 2015 Apr;56(4):560-6. doi: 10.2967/jnumed.114.149732. Epub 2015 Mar 5.

PMID:
25745091
5.

Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment.

Mattsson N, Tosun D, Insel PS, Simonson A, Jack CR Jr, Beckett LA, Donohue M, Jagust W, Schuff N, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Brain. 2014 May;137(Pt 5):1550-61. doi: 10.1093/brain/awu043. Epub 2014 Mar 12.

6.

Mapping the effects of ApoE4, age and cognitive status on 18F-florbetapir PET measured regional cortical patterns of beta-amyloid density and growth.

Murphy KR, Landau SM, Choudhury KR, Hostage CA, Shpanskaya KS, Sair HI, Petrella JR, Wong TZ, Doraiswamy PM; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2013 Sep;78:474-80. doi: 10.1016/j.neuroimage.2013.04.048. Epub 2013 Apr 23.

7.

Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study.

Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gomez MG, Langois CM, Langbaum JB, Ayutyanont N, Roontiva A, Thiyyagura P, Lee W, Mo H, Lopez L, Moreno S, Acosta-Baena N, Giraldo M, Garcia G, Reiman RA, Huentelman MJ, Kosik KS, Tariot PN, Lopera F, Reiman EM.

Lancet Neurol. 2012 Dec;11(12):1057-65. doi: 10.1016/S1474-4422(12)70227-2. Epub 2012 Nov 6.

8.

Amyloid deposition, hypometabolism, and longitudinal cognitive decline.

Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, Weiner MW, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative.

Ann Neurol. 2012 Oct;72(4):578-86. doi: 10.1002/ana.23650.

9.

Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease.

Fleisher AS, Chen K, Liu X, Ayutyanont N, Roontiva A, Thiyyagura P, Protas H, Joshi AD, Sabbagh M, Sadowsky CH, Sperling RA, Clark CM, Mintun MA, Pontecorvo MJ, Coleman RE, Doraiswamy PM, Johnson KA, Carpenter AP, Skovronsky DM, Reiman EM.

Neurobiol Aging. 2013 Jan;34(1):1-12. doi: 10.1016/j.neurobiolaging.2012.04.017. Epub 2012 May 24.

PMID:
22633529
10.

Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.

Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, Adler LP, Kovnat KD, Seibyl JP, Arora A, Saha K, Burns JD, Lowrey MJ, Mintun MA, Skovronsky DM; Florbetapir F 18 Study Investigators.

J Nucl Med. 2012 Mar;53(3):378-84. doi: 10.2967/jnumed.111.090340. Epub 2012 Feb 13.

11.

β-Amyloid is associated with aberrant metabolic connectivity in subjects with mild cognitive impairment.

Carbonell F, Charil A, Zijdenbos AP, Evans AC, Bedell BJ.

J Cereb Blood Flow Metab. 2014 Jul;34(7):1169-79. doi: 10.1038/jcbfm.2014.66. Epub 2014 Apr 16.

12.

Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid.

Landau SM, Lu M, Joshi AD, Pontecorvo M, Mintun MA, Trojanowski JQ, Shaw LM, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative.

Ann Neurol. 2013 Dec;74(6):826-36. doi: 10.1002/ana.23908.

13.

Cognition and amyloid load in Alzheimer disease imaged with florbetapir F 18(AV-45) positron emission tomography.

Rosenberg PB, Wong DF, Edell SL, Ross JS, Joshi AD, Brašić JR, Zhou Y, Raymont V, Kumar A, Ravert HT, Dannals RF, Pontecorvo MJ, Skovronsky DM, Lyketsos CG.

Am J Geriatr Psychiatry. 2013 Mar;21(3):272-8. doi: 10.1016/j.jagp.2012.11.016.

14.

Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study.

Doraiswamy PM, Sperling RA, Johnson K, Reiman EM, Wong TZ, Sabbagh MN, Sadowsky CH, Fleisher AS, Carpenter A, Joshi AD, Lu M, Grundman M, Mintun MA, Skovronsky DM, Pontecorvo MJ; AV45-A11 Study Group; AV45-A11 Study Group.

Mol Psychiatry. 2014 Sep;19(9):1044-51. doi: 10.1038/mp.2014.9. Epub 2014 Mar 11.

15.

Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.

Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, Joshi AD, Clark CM, Mintun MA, Pontecorvo MJ, Doraiswamy PM, Johnson KA, Skovronsky DM, Reiman EM.

Arch Neurol. 2011 Nov;68(11):1404-11. doi: 10.1001/archneurol.2011.150. Epub 2011 Jul 11.

PMID:
21747008
16.

Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios.

Landau SM, Fero A, Baker SL, Koeppe R, Mintun M, Chen K, Reiman EM, Jagust WJ.

J Nucl Med. 2015 Apr;56(4):567-74. doi: 10.2967/jnumed.114.148981. Epub 2015 Mar 5.

PMID:
25745095
17.

Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.

Villain N, Chételat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, Ames D, Martins RN, Eustache F, Salvado O, Masters CL, Rowe CC, Villemagne VL; AIBL Research Group.

Brain. 2012 Jul;135(Pt 7):2126-39. doi: 10.1093/brain/aws125. Epub 2012 May 23.

18.

Comparing predictors of conversion and decline in mild cognitive impairment.

Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, Petersen RC, Shaw LM, Trojanowski JQ, Jack CR Jr, Weiner MW, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2010 Jul 20;75(3):230-8. doi: 10.1212/WNL.0b013e3181e8e8b8. Epub 2010 Jun 30.

19.

Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia.

Trzepacz PT, Yu P, Sun J, Schuh K, Case M, Witte MM, Hochstetler H, Hake A; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2014 Jan;35(1):143-51. doi: 10.1016/j.neurobiolaging.2013.06.018. Epub 2013 Aug 15.

PMID:
23954175
20.

Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease.

Chételat G, Villemagne VL, Pike KE, Ellis KA, Bourgeat P, Jones G, O'Keefe GJ, Salvado O, Szoeke C, Martins RN, Ames D, Masters CL, Rowe CC; Australian Imaging Biomarkers and Lifestyle Study of ageing (AIBL) Research Group.

Brain. 2011 Mar;134(Pt 3):798-807. doi: 10.1093/brain/awq383. Epub 2011 Feb 9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk